Get the app
US › Healthcare

Verrica Pharmaceuticals Inc (VRCA)

US · Healthcare · Biotechnology

$4.65+2.65%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$5.9M
Revenue YoY
-53.8%
Net profit
$-13.2M
Profit YoY
-6547.5%
EPS
$-0.54
EPS estimate
$-0.47
Net margin
-224.4%

EPS came in at -0.54 against a street estimate of -0.47 — a miss of 14.9%.

Key statistics

Market cap
$85.0M
Forward P/E
0.0
P/B
20.18
Book value
$0.25
EPS (TTM)
$-1.70
52-week high
$9.82
52-week low
$3.28
50-day MA
$5.41
200-day MA
$6.27
Beta
1.50

Analyst view

Analysts rate Verrica Pharmaceuticals Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $13.83.

Shareholding

Insiders
49.00%
Institutions
27.14%

Largest institutional holders

FundStake
Caligan Partners LP5.38%
Cannell Capital LLC4.56%
Affinity Asset Advisors, LLC4.12%
Armistice Capital, LLC3.02%
Velan Capital Investment Management LP2.75%
BOOTHBAY FUND MANAGEMENT, LLC1.63%
Vanguard Capital Management, LLC1.10%
Dafna Capital Management LLC0.89%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Verrica Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.